Resources from the same session
1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Presenter: Jennifer Chan
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1142O - Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206)
Presenter: Ramon Salazar Soler
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1141O and 1142O
Presenter: Nicola Fazio
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Webcast
1143O - Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications
Presenter: Carlos Carretero-Puche
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1144O - Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
Presenter: Alberto Lens-Pardo
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1143O and 1144O
Presenter: Talya Dayton
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Slides
Webcast